JSJoão Cândido Spezia de Souza

João Cândido Spezia de Souza

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


João Cândido Spezia de Souza has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Vagus nerve stimulation in pediatric patients with Lennox–Gastaut syndrome: a systematic review

    by João Cândido Spezia de Souza, Marina Ilha Zimmermann, Natan Lucca Lima, Maruí Weber Corseuil Giehl, Ana Carolina Lobor Cancelier

  • Regorafenib in adult patients with recurrent glioblastoma: a single-arm meta-analysis

    by Marcos Henrique da Silva Mezzari, Natan Lucca Lima, Bárbara Ghizoni Maggi, Davi Orli Machado Grüdtner, João Cândido Spezia de Souza, Luis Henrique Correa de Lara, Gustavo Rassier Isolan

    Glioblastoma is an aggressive brain tumor with median survival under 2 years despite standard therapy. At recurrence, treatment options are limited, and regorafenib has emerged as a promising option. A systematic search was conducted through Pubmed, Cochrane Library, Embase, and Web of Science for studies on regorafenib in adult recurrent glioblastoma, and a single-arm meta-analysis with random-effects model was performed to pool the data. Across ten studies (724 patients), median overall survival (OS) was 7.2 months and median progression-free survival (PFS) was 2.6 months, with a 12-month OS of 22.5% and a 6-month PFS of 14.9%. Disease control rate (DCR) was 36.1%, including stable disease (SD) of 26.6% and a partial response of 8.5%; progressive disease occurred in 60.9%, and grade 3-4 adverse events in 31.4%. Meta-regression suggested MGMT methylation was associated with improved OS, PFS, DCR, and SD, while male sex was associated with better OS and SD. Overall, regorafenib demonstrated a predictable safety profile in recurrent glioblastoma, with outcomes potentially improved in male patients with MGMT-methylated tumors.


  • Early venous filling following reperfusion therapy in acute ischemic stroke: a systematic review and meta-analysis

    by Natan Lucca Lima, Marcos Henrique da Silva Mezzari, Luís Cláudio Izidio Costa Júnior, Davi Orli Machado Grüdtner, Bárbara Ghizoni Maggi, Darlos Kelvin de Azevedo, João Cândido Spezia de Souza, Wilson Jordão Mota Bezerra Júnior, Yasmin Guimarães Rodrigues, Gustavo Rassier Isolan

    Background Early venous filling (EVF), detected by digital subtraction angiography after endovascular therapy, may indicate hyperperfusion and vascular injury. Emerging evidence suggests that EVF is associated with adverse outcomes and complications, highlighting its potential role as a prognostic imaging marker in acute ischemic stroke (AIS). Methods A systematic search was conducted in the MEDLINE, Embase, Cochrane Library, and Web of Science databases to identify studies evaluating the outcomes of EVF following reperfusion therapy in cases of AIS. The outcomes included hemorrhagic transformation (HT), parenchymal hematoma (PH), hemorrhagic infarction (HI), symptomatic intracranial hemorrhage (sICH), cerebral infarction as hypodensity on imaging, malignant brain edema (MBE), and unfavorable outcome measured by modified Rankin scale (mRS ≥ 3) after 90 days. A meta-analysis using a random-effects model was conducted to pool the data. Results In the data analyses of 12 studies and 2,446 patients, the presence of EVF post-reperfusion was associated with increased risks of HT (odds ratio [OR] = 4.31; 95% confidence interval [CI] [3.00, 6.21]; p < 0.001), PH (OR = 5.73; 95% CI [2.82, 11.65]; p < 0.001), sICH (OR = 6.43; 95% CI [3.49, 8.47]; p < 0.001), cerebral infarction (OR = 15.95; 95% CI [6.37, 39.92]; p < 0.001), MBE (OR = 3.69; 95% CI [2.26, 6.04]; p < 0.001), and unfavorable functional outcomes (OR = 2.58; 95% CI [1.27, 5.23]; p = 0.009). Conclusions EVF may serve as a predictor of increased risk of hemorrhagic events, cerebral infarction on imaging, MBE, and unfavorable functional outcomes after brain reperfusion therapy. Graphical Abstract